At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Short Term Choline Supplementation and Cardiometabolic Health in Adults
In Brief
A clinical study evaluating Choline and Placebo for Cardiovascular Risk Factor. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Trimethylamine-N-oxide (TMAO), a metabolite produced by gut microbial metabolism of dietary choline, has recently been causally linked to atherosclerosis in animal models and has been shown to be predictive of cardiovascular disease (CVD) risk in some but not all cohort studies. The relevance of observations in animals to humans is unclear and little information is available on the mechanisms linking TMAO to increased CVD risk. Vascular dysfunction plays a critical role in the initiation and progression of atherothrombotic disease. Whether TMAO impairs vascular function in humans is not known. The purpose of this study is to determine if short term supplementation of dietary choline, which increases TMAO, affects CVD risk factors, such as glucose homeostasis and vascular function.
Study Details
Timeline
Interventions
1000 mg (2 x 500 mg) choline bitartrate capsules (over-the-counter supplement)
Choline-matched 1000 mg (2 x 500 mg) placebo (maltodextrin) capsules